|
|
Galmed Pharmaceuticals Ltd.
|
| General Information |
| Business: |
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing our proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. We believe that our product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis, or NASH, which is a chronic disease that constitutes a large unmet medical need. NASH is a severe form of Non-Alcoholic Fatty Liver Disease, or NAFLD, which is characterized by inflammation in the liver in addition to the presence of excess liver fat. NASH is often discovered incidentally, often times by elevated liver enzyme levels in blood tests. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
10 |
Founded: |
2000 |
|
| Contact Information |
| Address: |
8 Shaul Hamelech Blvd., Amot Hamishpat Bldg. Tel Aviv, IL 64733 |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -17.5 mil (last 12 months) |
|
| IPO Profile |
|
|
|
|
